Active clinical trials for "Psychomotor Agitation"

PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST) The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1 o The RASS is a well validated standardized score to measure a patient's agitation The secondary outcomes are Time until RASS returns to 0 or 1 if RASS <0 Need for additional sedation Adverse effects (need for intubation, arrhythmia) Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol Identification of potential study patients will be per state protocols Exclusion Criteria for the study Age <18 Pregnant Allergic to study medication Transport to hospital other than Mercy Fitzgerald Hospital Unable to reach medical command prior to giving medication When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study If the medical command agrees the patient is appropriate for the study, patients will be randomized to Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65) Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age ≥65) The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453 Richmond Agitation Sedation Scale RASS RASS Description 4 Combative, violent, danger to staff 3 Pulls or removes tube(s) or catheters; aggressive 2 Frequent non-purposeful movement 1 Anxious, apprehensive, but not aggressive 0 Alert and calm 1 Awakens to voice (eye opening/contact) >10 sec 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec 3 Moderate sedation, movement or eye opening. No eye contact 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation 5 Unarousable, no response to voice or physical stimulation

The aims of the trial are to assess the safety and the efficacy of SPM 962 following once-a-daily transdermal administration within a range of 2.25 to 6.75 mg/day in Japanese patients with restless legs syndrome (RLS) in a multi-center, open-label trial. The maximum treatment period is 53 weeks. The trial is an extension trial from the precedent 6-week, double-blind, randomized, placebo-controlled, parallel-group comparative trial(243-07-003). The trial is also for an exploratory investigation of incidence of augmentation, the most problematic complications in dopaminergic treatment.

Haloperidol is known to be a safe alternative medication to control difficult pain, and has been shown effective when compared to placebo for controlling headaches. Investigators hypothesized that the combination of haloperidol and diphenhydramine would be a useful medication choice for migraine headache patients in the emergency department in comparison to a common migraine treatment regimen of metoclopramide and diphenhydramine.

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with moderate to severe Restless Legs Syndrome.

The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in idiopathic and uremic RLS patients with regard to efficacy, safety, and quality of life.

We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks

Periodic Limb Movements (PLMs) during sleep in patients with Restless Legs Syndrome (RLS) have been shown to be associated with elevations in Blood Pressure (BP). Rotigotine has been shown to effectively reduce the incidence of PLMs in patients with RLS. The current study aims to demonstrate that treatment with Rotigotine could help reduce the number of nocturnal BP elevations associated with PLMs in patients with RLS.